Core Viewpoint - The article discusses the backlash from Huaxi Biological against the notion that hyaluronic acid is "outdated," attributing this perspective to a misleading narrative constructed by "restless capital" and certain brokerage reports [1][4]. Group 1: Market Dynamics - Huaxi Biological published an article refuting the "outdated hyaluronic acid" claim, stating that this narrative undermines the efforts of Chinese scientists and the industry [1]. - The rise of the "outdated hyaluronic acid" theory is seen as a tactic to divert attention from the necessary evolution of the industry, pushing capital towards new themes [4]. Group 2: Brokerage Reports - Multiple brokerage reports, including those from Western Securities, were specifically named by Huaxi Biological for spreading misleading comparisons that favor a collagen company over the hyaluronic acid industry [6]. - Huaxi Biological emphasized that these misleading conclusions have been widely disseminated by media and influencers, creating a negative perception that harms the market foundation of a competitive Chinese industry [6]. Group 3: Financial Performance - Huaxi Biological's stock price peaked at 309.43 CNY per share in July 2021 but has since been on a downward trend, closing at 50.60 CNY on May 19, 2023, reflecting a long-term decline [9][12]. - The company reported a significant drop in revenue from its skin science innovation business, which accounted for nearly half of its revenue, with a year-on-year decline of 31.62% [11]. Group 4: Market Position - Huaxi Biological's market capitalization has decreased from over 1,400 billion CNY at its peak to approximately 244 billion CNY currently [12]. - In contrast, competitors like Juzhi Biological and Jinbo Biological have seen their market values rise significantly, with Juzhi Biological nearing 900 billion HKD and Jinbo Biological's stock price doubling recently [15].

Group 1 - The article emphasizes that the collagen protein concept has gained attention in the capital market since 2022, overshadowing the hyaluronic acid industry, which has been misrepresented in various research reports [1] - It highlights that misleading conclusions comparing collagen protein to hyaluronic acid have been widely circulated, damaging the market foundation of a competitive Chinese industry [1] - The rise of the "outdated hyaluronic acid" narrative is described as a phenomenon driven by "impatient capital," which attempts to divert focus from the necessary evolution of the industry [1] Group 2 - The article points out that while hyaluronic acid is being simplistically labeled as just a "moisturizer," there is a significant increase in research surrounding it, with approximately 47,000 published papers from 2000 to 2024 [2] - Over 60% of the research on hyaluronic acid focuses on advanced fields in life sciences, including immunity, metabolism, cell differentiation, cancer research, and signaling mechanisms [2]

Market Overview - The Shanghai Composite Index fell by 0.40% on May 16, with 15 industries experiencing gains, led by the automotive and machinery sectors, which rose by 1.91% and 0.83% respectively [1] - The beauty and personal care sector had the largest decline, dropping by 1.31%, followed by the non-bank financial sector, which fell by 1.21% [1] Capital Flow Analysis - The net inflow of capital in the two markets was 307 million yuan, with 14 industries seeing net inflows. The automotive sector led with a net inflow of 4.616 billion yuan, while the basic chemical industry had a net inflow of 1.981 billion yuan and a daily increase of 0.60% [1] - Conversely, 17 industries experienced net outflows, with the non-bank financial sector seeing the largest outflow of 1.925 billion yuan, followed by the transportation sector with a net outflow of 1.250 billion yuan [1] Beauty and Personal Care Sector - The beauty and personal care sector saw a decline of 1.31% with a net outflow of 294 million yuan. Out of 31 stocks in this sector, 11 rose while 20 fell [2] - The stocks with the highest net inflow included Qingdao Kingking with 50.67 million yuan, followed by Zhongshun Jierou and Yiyi Co., with net inflows of 20.55 million yuan and 9.64 million yuan respectively [2] - Notable stocks with significant net outflows included Furuida with 151 million yuan, Aimeike with 49.19 million yuan, and Qingsong Co. with 38.32 million yuan [2] Individual Stock Performance - The top stocks in the beauty and personal care sector based on capital flow include: - Furuida: -3.82% with a net outflow of 150.98 million yuan [3] - Aimeike: -2.06% with a net outflow of 49.19 million yuan [3] - Qingsong Co.: -7.34% with a net outflow of 38.32 million yuan [3] - Other notable performers include: - Qingdao Kingking: +1.89% with a net inflow of 50.67 million yuan [3] - Zhongshun Jierou: +0.87% with a net inflow of 20.55 million yuan [3]

Core Viewpoint - The medical beauty industry is experiencing a significant performance divergence among listed companies, driven by a shift from hyaluronic acid to collagen products, indicating a potential restructuring of industry value logic [1][3]. Group 1: Performance Analysis - In 2024, the performance of upstream medical beauty companies showed significant divergence, with companies like Juzi Biological and Jinbo Biological leading with high growth rates, while major hyaluronic acid players like Aimeike, Huaxi Biological, and Haohai Biological faced pressure [2][3]. - Aimeike's revenue growth slowed to 5.45%, the lowest since its listing, while Huaxi Biological's revenue declined by 11.61% and net profit dropped by 70.59% [3][5]. - Juzi Biological achieved revenue of 5.539 billion, a year-on-year increase of 57.2%, and a net profit of 2.062 billion, up 42.4% [5][7]. Group 2: Market Trends - The market for recombinant collagen products in China is projected to grow from 18.5 billion in 2022 to 108.3 billion by 2027, with a compound annual growth rate of 42.4% [7]. - Companies are increasingly entering the collagen market, including Aimeike and Huaxi Biological, which are exploring new opportunities in this segment [7][8]. - Huaxi Biological is developing proprietary recombinant human collagen products that have entered clinical trials, indicating a strategic shift towards innovative product development [7].

Core Insights - The analysis focuses on the inventory status of 14 representative listed companies in the daily chemical skincare sector for the year 2024, highlighting trends in inventory scale and turnover efficiency [1][2]. Inventory Scale and Proportion - Over half of the selected skincare companies experienced growth in inventory scale in 2024, with Chuang'er Biological showing the highest year-on-year increase of 62.44%, reaching an inventory scale of 0.35 billion [2][3]. - Other companies with significant inventory growth include Kesi Co. (0.97 billion, up 47.96%), Jinbo Biological (0.97 billion, up 45.68%), and Fulejia (1.6 billion, up 30.26%) [2][3]. - Water Sheep Co. has the highest inventory proportion relative to total assets at approximately 19.52% in 2024, indicating a notable increase from 19.32% in 2023 [4]. Inventory Turnover Efficiency - Among the analyzed companies, only Marubi and Qingsong Co. showed improvement in inventory turnover efficiency, while the remaining eight companies experienced an increase in inventory turnover days, indicating a decline in efficiency [1][5]. - Jinbo Biological, Huaxi Biological, and Beitaini reported inventory turnover days exceeding 270 days (approximately 9 months), with turnover days of 307.93 and 254.45 respectively for Jinbo and Huaxi [1][5]. - Eight out of the 14 companies improved their inventory turnover efficiency, while companies like Fulejia, Kesi Co., Marubi, Huaxi, Water Sheep, and Jiaheng Household experienced a decline in efficiency [7].

Group 1 - The concept of ergothioneine has gained significant attention in the A-share market, with stocks related to this concept experiencing strong price increases [2][3] - Key stocks in the ergothioneine sector include Tuoxin Pharmaceutical and Chuaning Biological, both of which reached their daily limit up, while other companies like Bawei Co., Xianle Health, and Huaxi Biological also saw gains [2][3] - The chairman of Kelun Pharmaceutical, Liu Gexin, has endorsed the company's anti-aging product "ergothioneine capsules," claiming to have used the product for three years, which has contributed to the product's popularity [2][3] Group 2 - Kelun Pharmaceutical reported a revenue of 4.39 billion yuan in Q1, a year-on-year decline of 29.42%, with a net profit of 584 million yuan, down 43.07% [2][4] - The decline in revenue and profit is attributed to high base effects from the previous year and the impact of centralized procurement on the infusion business [2][4] - The company aims to establish a new subsidiary, Kelun Yongnian, to focus on the sales of ergothioneine products, indicating a strategic shift towards the health industry [3][4] Group 3 - There are 14 stocks in the A-share market related to ergothioneine, with Huadong Medicine, Kelun Pharmaceutical, and Chuaning Biological having the largest market capitalizations [4] - The average stock price increase for ergothioneine-related stocks this year is 19.16%, with Ruoyuchen leading with a 104.62% increase [4] - Half of the ergothioneine concept stocks reported positive net profits in Q1, with companies like Changshan Pharmaceutical turning losses into profits [4] Group 4 - There was a significant net inflow of capital into ergothioneine concept stocks today, with Chuaning Biological, Jindawei, and Kelun Pharmaceutical seeing the highest net inflows of 563 million yuan, 153 million yuan, and 129 million yuan respectively [5]

证券时报•数据宝统计显示，今日科创板个股上涨的有88只，下跌的有487只。 资金流向方面，今日主力资金净流入的科创板股共有185只，其中，3只个股主力资金净流入超3000万 元，华熙生物主力资金净流入4047.09万元，净流入资金居首；光云科技、九号公司紧随其后，全天净 流入资金分别为3643.48万元、3420.34万元。主力资金净流出的有399只，净流出资金最多的是中芯国 际，该股今日下跌1.91%，全天主力资金净流出4.21亿元，其次是寒武纪、金山办公，主力资金净流出 分别为1.61亿元、1.21亿元。 从主力资金连续性进行观察，共有43只个股主力资金连续3个交易日以上持续净流入，连续净流入天数 最多的是瑞联新材、利扬芯片等2只股，主力资金均连续净流入9天。主力资金连续流出的个股有162 只，连续流出天数最多的是先锋精科，该股已连续21个交易日净流出；连续净流出天数较多的还有莱特 光电、三达膜等，主力资金分别连续流出14天、11天。（数据宝） 主力资金净流入排名 | 代码 | 简称 | 主力资金净流入（万元） | 主力资金流入率（%） | 涨跌幅（%） | 换手率（%） | | --- | --- | ...

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Composite Index (000680) decreased by 1.41% as of May 15, 2025, with mixed performance among constituent stocks [3] - Leading gainers included Junzhixing (688655) up 7.70%, Huaxi Biological (688363) up 6.56%, and Wanrun New Energy (688275) up 6.22%, while leading decliners were Changguang Huaxin (688048) down 8.10%, Huafeng Technology (688629) down 7.95%, and Aerospace Nanhu (688552) down 7.21% [3] - The Huaxia Sci-Tech Innovation Index ETF (589000) fell by 1.48%, with the latest price at 0.93 yuan, but showed a cumulative increase of 0.64% over the past two weeks as of May 14, 2025 [3] Group 2 - The Huaxia Sci-Tech Innovation Index ETF (589000) recorded a turnover rate of 3.73% during the trading session, with a transaction volume of 104 million yuan [3] - Over the past week, the average daily transaction volume of the Huaxia Sci-Tech Innovation Index ETF was 192 million yuan, ranking first among comparable funds [3] - In terms of scale and shares, the Huaxia Sci-Tech Innovation Index ETF saw an increase of 1.902 billion yuan in scale and 1.988 billion shares in volume over the past month, leading among comparable funds [3] Group 3 - The pharmaceutical sector is showing continuous signs of performance improvement for 2024 and Q1 2025, with overall profitability on the rise [4] - The sector is experiencing a gradual clearing of inventory and the impact of anti-corruption measures, with notable performance in sub-sectors such as chemical pharmaceuticals and medical consumables [4] - The overall R&D expense ratio for the pharmaceutical sector is expected to rebound year-on-year in 2024, laying a foundation for long-term stable development [4]

Core Insights - The 2025 China Beauty Expo (CBE) showcased the men's skincare brand "Kehan," co-developed by Huaxi Biological and New Seven Days Group, featuring its patented ingredient "Coresoy Essence" and a full product line [1] - Kehan won the "29th CBE Beauty Good Brand" award, establishing itself as a technological benchmark in the men's efficacy skincare sector with the brand philosophy "One Kehan, One Landing" [1][4] Product and Technology Highlights - Kehan's exhibition design was inspired by a "scientific laboratory," featuring interactive installations like the "Soybean Challenge" and "Capsule Toy Machine," which visually narrate the technology behind the core ingredient "Coresoy Essence" [2] - The "Soybean Challenge" game demonstrated the oil absorption process of Coresoy Essence, while the capsule machine introduced products like "Oil Control Cleansing Mousse" and "Lightweight Physical Sunscreen," distributing over 2000 samples on the first day [2][3] Ingredient Efficacy - Coresoy Essence, derived from non-GMO soybeans through patented fermentation, contains 14 amino acids and over 400 peptides, offering multiple benefits such as hydration, oil control, repair, anti-inflammation, whitening, antioxidant properties, and anti-aging [3] - In scratch tests, a concentration of 2.0%-4.0% of Coresoy Essence significantly accelerated skin healing, enhancing cell migration speed and reducing wound healing time, with a synergistic effect on hyaluronic acid (HA) of 13.64% [3] Market Positioning and Strategy - Kehan's product lineup, including the "Kehan Men's Three-in-One Multi-Effect Essence" and "Lightweight Physical Sunscreen," targets men's demand for efficient and simplified skincare, showcasing data like "12.5 hours of high-level sun protection" [4] - The brand emphasizes a scientific formula system "X+Y(y)+Z," aiming to break the traditional marketing-heavy approach in the men's skincare market, focusing on genuine, safe, and effective products [4][5] - With a comprehensive product range covering cleansing, sun protection, and essence, Kehan has established a full-chain barrier from raw material research to product innovation and precise marketing, currently available in offline channels like Watsons [4]

（文章来源：21世纪经济报道） 科创医药指数ETF（588700）紧密跟踪上证科创板生物医药指数，上证科创板生物医药指数从科创板市 场中选取50只市值较大的生物医药、生物医学工程、生物农业、生物质能、其他生物业等领域上市公司 证券作为指数样本，反映科创板市场代表性生物医药产业上市公司证券的整体表现。该ETF配备了2只 场外联接基金（A类：021060；C类：021061）。 中信建投研报表示，制药、CXO、上游及科学服务板块上周表现较好。展望2025年，我们继续看好优 质创新药公司，积极关注药械前沿技术；全球流动性有望继续改善，国家政策鼓励产业创新，我们继续 看好有全球竞争力的优质创新药公司。同时我们建议积极关注前沿技术，如创新药及制药（双抗及多 抗、TCE、核药等）、器械（AI、脑机接口等）。出海主线：着眼长远，不惧短期波动。长期看医药行 业有望走出全球性大公司，但投资人也需对出海带来的挑战有充分预期。 （本文机构观点来自持牌证券机构，不构成任何投资建议，亦不代表平台观点，请投资人独立判断和决 策。） 5月15日，创业板指、深成指跌逾1%。 热门ETF方面，科创医药指数ETF（588700）走势震荡，截至发 ...